A Deep Insight into the Correlation Between Gut Dysbiosis and Alzheimer’s Amyloidopathy

IF 0.4 Q4 PHARMACOLOGY & PHARMACY
S. Kondaveeti, Dithu Thekkekkara, Lakshmi Narayanan T, S. Manjula, Y. M. Tausif, Amrita Babu, S. Meheronnisha
{"title":"A Deep Insight into the Correlation Between Gut Dysbiosis and Alzheimer’s Amyloidopathy","authors":"S. Kondaveeti, Dithu Thekkekkara, Lakshmi Narayanan T, S. Manjula, Y. M. Tausif, Amrita Babu, S. Meheronnisha","doi":"10.1177/0976500X221150310","DOIUrl":null,"url":null,"abstract":"Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD. The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment. Pictorial Abstract","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"13 1","pages":"305 - 315"},"PeriodicalIF":0.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0976500X221150310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD. The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment. Pictorial Abstract
肠道营养不良与阿尔茨海默病淀粉样变性相关性的深入研究
最近的研究表明,肠道生态失调与阿尔茨海默病(AD)之间存在着强烈的相关性。这篇综述的目的是研究肠道微生态失调、免疫系统激活和AD发病之间的关系,并考察微生物群靶向AD治疗的最新突破。对科学文献进行了综述,以评估肠道微生态失调与AD之间的相关性以及各种相关因素。肠道微生态失调会增加有害物质,如细菌淀粉样蛋白,使肠道屏障和血脑屏障更具渗透性。这导致免疫反应的刺激和细胞因子如白细胞介素-1β(IL-1β)的增加。因此,肠道生态失调加速了AD的进展。这篇综述强调了肠道生态失调与AD之间的联系,以及微生物群靶向治疗AD的潜力。图片摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
37
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信